Medical Innovation Recedes Along With Venture Capital

May 2013
Investors Business Daily;5/15/2013, pA13
Venture capital investment in American life-sciences innovation is suffering an alarming decline. The number of new biotechnology and medical device companies receiving start-up financing has now fallen to the lowest levels in 18 years, according to PriceWaterhouseCoopers.


Related Articles

  • Same Old Story? Barbella, Michael // Medical Product Outsourcing;Nov/Dec2013, Vol. 11 Issue 9, p32 

    The article presents information on medtech in the U.S. It mentions about decreasing venture capital funding for medical devices, and rising regulations on medical products companies. It also mentions about the challenges faced by the industry in introducing innovative products in the market,...

  • Can Technology Fix Medicine? Byrnes, Nanette // MIT Technology Review;Sep/OCt2014, Vol. 117 Issue 5, p65 

    The article discusses data-driven health care and the question of whether technology can fix medicine, focusing on the reported popularity of medical data in relation to venture investing and product innovation. Molecular, environmental, and behavioral information about medical patients are...

  • Defibrillator Maker Cameron Drawing Attention. Reed, Vita // Orange County Business Journal;7/26/2010, Vol. 33 Issue 30, p3 

    The article reports on the innovation of defibrillator product of Cameron Health Inc., a venture capital-backed medical device maker in San Clemente, California.

  • Funding boost for start-ups.  // Australian Life Scientist;May/Jun2013, Vol. 10 Issue 3, p10 

    The article reports on the three venture capital funds that will invest to support small businesses in Australia such as GBS Venture Partners, Carnegie Venture Capital, and Innovation Capital Associates.

  • Not Venturing Out on Their Own. Weeks, Katie // San Diego Business Journal;10/24/2005, Vol. 26 Issue 43, p17 

    Reports on the reliance of medical devices or new technologies rely on venture capital funds based on a research conduced in the U.S. Consideration of merging deals as an alternative to venture capital for startup companies; Use of corporate funds for marketing its product; Role of yearning for...

  • A little bit of Sass goes a long way. Jacklet, Ben // Oregon Business Magazine;Jul2010, Vol. 33 Issue 7, p11 

    The article reports on the venture capital fund, Biomed Innovation Fund launched by Dick Sass in collaboration with medical devices expert, Brian Brandell and investors Wayne Embree and Brock Metcalf.

  • Delphinus raises $39.5M for cancer detector.  // Crain's Detroit Business;9/14/2015, Vol. 31 Issue 37, p0034 

    The article reports on the venture capital amount raised by Delphinus Medical Technologies Inc., an innovative leader in advanced sound transmission and capture, that will be used to finance the trials of its SoftVue System for breast cancer detection.

  • Venture capital and private equity: Financing innovation in the private sector. Pavey, Robert D. // Canada-United States Law Journal;1995, Vol. 21, p203 

    Presents speech given by the General Partner of Morganthaler Ventures, about financing of innovation in terms of venture capital and private equity. Benefits of small business investment corporations; Venture capital in the 1980s; Cycle of venture capital disbursements.

  • Hospital manages to convert intellectual capital to profit. Costello, Mary Ann // AHA News;8/13/2001, Vol. 37 Issue 32, p2 

    Deals with the Overlake Venture Center, an incubator for innovative health care service created by the Overlake Hospital Medical Center in Bellevue, Washington to convert their intellectual capital to profit. Goal of the Doctor Goodwell venture; Other idea being developed by the center; Remarks...

  • Ongoing challenges loom for VCs and CEOs in the new year. Pedersen, Amanda // Medical Device Daily;1/3/2012, Vol. 16 Issue 1, p1 

    The article reports on the expectations of venture capitalists and chief executive officers (CEO) in the medical device sector for 2012, based on the Venture view predictions survey. Bob Paulson of NxThera forecasts progress difficulties in raising capital and slow improvement in regulatory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics